FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
This is a Phase 1 dose-finding study of FT536 given in combination with a monoclonal antibody following lymphodepletion in participants with advanced solid tumors. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Non Small Cell Lung Cancer|Colorectal Cancer|Breast Cancer|Ovarian Cancer|Pancreatic Cancer|Head and Neck Cancer|GastroEsophageal Cancer
DRUG: FT536|DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: IL-2|COMBINATION_PRODUCT: Avelumab|COMBINATION_PRODUCT: Pembrolizumab|COMBINATION_PRODUCT: Nivolumab|COMBINATION_PRODUCT: Atezolizumab|COMBINATION_PRODUCT: Trastuzumab|COMBINATION_PRODUCT: Cetuximab|COMBINATION_PRODUCT: Amivantamab|DRUG: IL-2
Determine the Recommended Phase 2 Dose (RP2D), The RP2Ds of FT536 monotherapy and FT536 + monoclonal antibody (mAbs) will be determined. The RP2D will be determined based on the overall safety and efficacy profile., Up to approximately 3 years|Number of Participants with â‰¥ Adverse Event (AE) according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v5.0, The safety and tolerability of FT536 monotherapy and in combination with mAbs will be determined., Following enrollment completion within dose escalation and expansion, approximately 3 years
This is a Phase 1 dose-finding study of FT536 given in combination with a monoclonal antibody following lymphodepletion in participants with advanced solid tumors. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.